Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications - Trial NCT06401642
Access comprehensive clinical trial information for NCT06401642 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Migraine. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mayo Clinic
Timeline & Enrollment
Phase 4
May 01, 2024
Mar 01, 2027
Primary Outcome
Headache relief in 2 hours,Headache relief in 4 hours,Functional disability level in 2 hours,Functional disability level in 4 hours
Summary
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in
 the US. The purpose of this study is to investigate the effectiveness and tolerability of
 zavegepant for the acute treatment of migraine attacks amongst participants who are using
 calcitonin gene-related peptide (CGRP) migraine preventive treatments.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06401642
Non-Device Trial